| Project/Area Number |
22890084
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
WANG Linan 三重大学, 大学院・医学系研究科, 特任助教 (00589484)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,068,000 (Direct Cost: ¥2,360,000、Indirect Cost: ¥708,000)
Fiscal Year 2011: ¥1,469,000 (Direct Cost: ¥1,130,000、Indirect Cost: ¥339,000)
Fiscal Year 2010: ¥1,599,000 (Direct Cost: ¥1,230,000、Indirect Cost: ¥369,000)
|
|---|
| Keywords | MAGE-A4 / NOG mouse / CEA / T-body / TCR / scFv |
|---|
| Research Abstract |
Adoptive cell therapy(ACT) for cancer, in which T cells are collected from patient's peripheral blood, modified by the transduction of tumor-antigen specific T cell receptor(TCR) and re-administered to the same patient, is increasingly the subject of clinical trials. In this study, we aimed to establish a mouse model to analyze "in vivo" functions of the transferred T cells by utilizing immunocompromised(NOG) mice. We observed the regression of transplanted human esophageal tumor(HLA-A2402+, MAGE-A4+) growth only when T cells modified to express TCR, recognizing MAGE-A4(p143-151) peptide in the context of HLA-A2402, were co-administered. This model will provide us more detailed information about mechanism of efficacies of transferred T cells.
|
